newsfilter
← Latest News
GlobeNewswire·

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

PRAX
  • Praxis Precision Medicines will present expanded Phase 3 Essential3 data for ulixacaltamide in essential tremor at the 2026 AAN Annual Meeting in Chicago from April 18–22, 2026.
  • Ulixacaltamide is a T-type calcium channel inhibitor that received FDA Breakthrough Therapy Designation based on the first positive Phase 3 program in essential tremor.
  • The company will present 3 oral presentations & 12 posters at the meeting, including a plenary session on Essential3 results on Tuesday, April 21.
  • Additional presentations will cover clinical updates from the elsunersen ASO program for SCN2A-DEE & data on the Vormatrigine & Relutrigine epilepsy pipelines.
  • Praxis will host an in-booth speaker showcase at Booth #2324 to discuss Essential3 findings & the broader unmet need in essential tremor.
  • Essential tremor affects approximately 7 million people in the US, & ulixacaltamide aims to provide meaningful improvements in daily function for patients.
  • Vormatrigine is being evaluated in the POWER1 Phase 2/3 study for focal onset seizures, following positive results from the RADIANT study.
  • Relutrigine has received FDA Orphan Drug & Rare Pediatric Disease Designations for SCN2A-DEE, SCN8A-DEE, & Dravet syndrome.
  • Elsunersen is an antisense oligonucleotide targeting SCN2A mutations, currently developed in collaboration with Ionis Pharmaceuticals & RogCon.
  • Scientific materials from the presentations will be available on the AAN meeting page & the Praxis website following the event.